When the device detects sufficient change in the optical properties of the tissue, it sounds an alarm. The company reports that its technology is very good at keeping low the number of false positives.
We recently interviewed Gary Warren, the President and CEO of ivWatch, who gave us an in-depth perspective on the company’s technology and its applications. In the latest announcement, Gary said.
“Peripheral IV therapy is among the most common invasive hospital procedures performed worldwide. Having the ability to extend the only surveillance monitoring technology for early detection of these common IV complications to new markets will help improve patient safety and effectiveness of IV therapy on a much larger scale.”
“Navigating the comprehensive process to secure these regulatory milestones not only makes ivWatch positioned for growth but gives us the ability to respond quickly to new opportunities.”
The device already has FDA clearance and is available for direct purchase from the company by hospitals and clinics.
